CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.44B, above the global median of $1.15B
- FinancialsAltman Z-Score 2.28: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.44BUSDvs all stocks (USD)
Revenue (TTM)
236.00MUSDvs all stocks (USD)
Profit Margin
-156.36%vs Biotechnology peers
Beta
0.7990xvs all stocks
52-Week Change
195.57%vs all stocks
Market Capitalization
3.44BUSDvs all stocks (USD)
Enterprise Value
2.85BUSDvs all stocks (USD)
Forward P/E
-8.82xvs Biotechnology peers
Price to Sales (TTM)
14.59xvs Biotechnology peers
Price to Book (MRQ)
6.56xvs Biotechnology peers
Enterprise to Revenue
12.09xvs Biotechnology peers
Enterprise to EBITDA
-7.33xvs Biotechnology peers
Profit Margin
-156.36%vs Biotechnology peers
Operating Margin
-788.24%vs Biotechnology peers
Return on Assets (TTM)
-23.11%vs Biotechnology peers
Return on Equity (TTM)
-69.95%vs Biotechnology peers
Revenue (TTM)
236.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.07USDUpdated Jul 19, 2026Quarterly Revenue Growth
-39.30%vs Biotechnology peers
Gross Profit (TTM)
-287.00MUSDvs all stocks (USD)
EBITDA (TTM)
-389.00MUSDvs all stocks (USD)
Net Income (TTM)
-369.00MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-39.29%vs Biotechnology peers
Operating Cash Flow (TTM)
-488.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-156.00MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
247.00MUSDFY2025 · Dec 31, 2025Operating Income
-386.00MUSDvs all stocks (USD)
Pre-tax Income
-353.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-353.00MUSDFY2025 · Dec 31, 2025EBIT
-345.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-335.00MUSDFY2025 · Dec 31, 2025Research & Development
523.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
110.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
41.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.00MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-353.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-469.00MUSDFY2025 · Dec 31, 2025Free Cash Flow
-471.00MUSDDerived from operating cash flow minus capital expenditure. This filing charges 10M of depreciation against 2M of capital expenditure, and its own free-cash-flow line reads -484M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
225.00MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
7.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-353.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
10.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
60.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
8.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
9.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
24.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-227.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.08BUSDFY2025 · Dec 31, 2025Sale of Investments
1.14BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
66.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
49.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
478.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
125.50MSharesUpdated Jul 19, 2026Float Shares
88.98MSharesUpdated Jul 19, 2026Shares Short
12.64MSharesUpdated Jul 19, 2026Short Ratio
7.62daysvs all stocks
Short % of Shares Outstanding
16.54%vs all stocks
% Held by Insiders
29.15%vs all stocks
% Held by Institutions
72.33%vs all stocks
Total Cash (MRQ)
822.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.54USDUpdated Jul 19, 2026Total Debt (MRQ)
232.00MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4427xvs Biotechnology peers
Current Ratio (MRQ)
4.04xvs Biotechnology peers
Book Value per Share (MRQ)
4.17USDUpdated Jul 19, 2026Total Assets
1.14BUSDvs all stocks (USD)
Total Current Assets
1.01BUSDFY2025 · Dec 31, 2025Total Liabilities
508.00MUSDFY2025 · Dec 31, 2025Total Non-current Assets
132.00MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
277.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
231.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
222.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
759.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
11.00MUSDFY2025 · Dec 31, 2025Accounts Payable
42.00MUSDFY2025 · Dec 31, 2025Short-term Debt
13.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
35.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
18.00MUSDFY2025 · Dec 31, 2025Long-term Debt
99.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
135.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.12BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.49BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
631.00MUSDvs all stocks (USD)
52-Week Low
8.84USDUpdated Jul 19, 202652-Week High
31.73USDUpdated Jul 19, 202652-Week Change
195.57%vs all stocks
Beta
0.7990xvs all stocks
50-Day MA
26.07USDUpdated Jul 19, 2026200-Day MA
22.58USDUpdated Jul 19, 2026Avg 10-Day Volume
881.74KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.44MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.17USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.28: grey zoneSignificant
Altman Z-Score: 2.28
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.44B, above the global median of $1.15BNotable
Market cap (USD): 3,442,411,443Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Hubei Jumpcan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Nhwa Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hanmi Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow